MAKENZIE BARTLING: Open Payments
NPI 1568184224 · CHANDLER, AZ. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$826 in 42 payments from 16 companies in 2025. Trend: 2023 $662 · 2024 $969 · 2025 $826
Food & beverage: $826
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 11 | $178 |
| Takeda Pharmaceuticals U.S.A., Inc. | 4 | $102 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | 6 | $100 |
| Gilead Sciences, Inc. | 4 | $70 |
| Ipsen Biopharmaceuticals, Inc | 3 | $66 |
| Ardelyx, Inc. | 2 | $53 |
| Novo Nordisk Inc | 2 | $45 |
| QOL Medical, LLC | 2 | $43 |
| GENZYME CORPORATION | 1 | $29 |
| Madrigal Pharmaceuticals | 1 | $27 |
Products named: ENTYVIO, XIFAXAN, IQIRVO, RINVOQ, LINZESS, IBSRELA, DUPIXENT, SKYRIZI.
Industry payments across AZ — which companies pay providers there.
